The ARPC1B Knockout HeLa Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population derived from the HeLa human cervical adenocarcinoma cell line, in which the ARPC1B gene has been disrupted to generate a loss-of-function model. These polyclonal cells offer a heterogeneous pool of edited alleles, enabling functional studies without clonal selection bias.
HeLa cells are an immortalized epithelial cell line originally isolated from a cervical adenocarcinoma of a 31-year-old African American woman, widely utilized in cancer biology, cell biology, and drug discovery due to their robust growth and well-characterized signaling networks. This host background provides a consistent and reproducible system for investigating cytoskeletal dynamics and associated pathologies.
ARPC1B encodes the p41 subunit of the actin-related protein 2/3 (Arp2/3) complex, a seven-subunit assembly that nucleates branched actin filaments. The Arp2/3 complex is activated by nucleation-promoting factors such as WASP, N-WASP, and the WAVE complex, which respond to upstream Rho-family GTPases including Rac1 and Cdc42, as well as PIP3. ARPC1B directly interacts with other Arp2/3 subunits (ARP2, ARP3, ARPC2-5), actin monomers, and cortactin, facilitating the formation of branched F-actin networks that drive lamellipodium extension, cell migration, endocytosis, and phagocytosis.
In HeLa cells, ARPC1B knockout disrupts the integrity and function of the Arp2/3 complex, impairing actin polymerization and branched network assembly. This leads to defective lamellipodia formation, reduced migratory capacity, and compromised endocytic and phagocytic processes. The model is therefore highly relevant for investigating actin cytoskeleton-related pathologies including combined immunodeficiency, myelodysplasia, and autoinflammatory disorders, as well as for studying cancer cell motility and invasion where actin dynamics are frequently dysregulated.
Researchers can employ these cells in diverse assays, such as western blotting to verify ARPC1B loss, immunofluorescence staining of F-actin and lamellipodia markers, scratch-wound migration assays, flow cytometric analysis of endocytosis, and co-immunoprecipitation to assess Arp2/3 complex integrity. Additional applications include RT-qPCR for ARPC1B expression, actin polymerization assays, phagocytosis assays, and drug screening for cytoskeletal inhibitors. This knockout polyclonal population serves as a versatile tool for delineating Arp2/3-dependent mechanisms in cell motility, immune cell function, and cancer. For further information, please contact Ascent Research.
